miR-106b-5p protects against drug-induced liver injury by targeting vimentin to stimulate liver regeneration

Abstract

Understanding the endogenous mechanism of adaptive response to drug-induced liver injury (arDILI) may discover innovative strategies to manage DILI. To gain mechanistic insight into arDILI, we investigated exosomal miRNAs in the adaptive response to toosendanin-induced liver injury (TILI) of mice. Exosomal miR-106b-5p was identified as a specific regulator of arDILI by comprehensive miRNA profiling. Outstandingly, miR-106b-5p agomir treatment alleviated TILI and other DILI by inhibiting apoptosis and promoting hepatocyte proliferation. Conversely, antagomir treatments had opposite effects, indicating that miR-106b-5p protects mice from liver injury. Injured hepatocytes released miR-106b-5p-enriched exosomes taken up by surrounding hepatocytes. Vim (encodes vimentin) was identified as an important target of miR-106b-5p by dual luciferase reporter and siRNA assays. Furthermore, single-cell RNA-sequencing analysis of toosendanin-injured mouse liver revealed a cluster of Vim⁺ hepatocytes; nonetheless declined following miR-106b-5p cotreatment. More importantly, Vim knockout protected mice from acetaminophen poisoning and TILI. In the clinic, serum miR-106b-5p expression levels correlated with the severity of DILI. Indeed, liver biopsies of clinical cases exposed to different DILI causing drugs revealed marked vimentin expression among harmed hepatocytes, confirming clinical relevance. Together, we report mechanisms of arDILI whereby miR-106b-5p safeguards restorative tissue repair by targeting vimentin.

Keywords

adaptive response / drug-induced liver injury / miRNAs / toosendanin / vimentin

References

[1] Rezkalla SH, Kloner RA. Ischemic preconditioning and preinfarction angina in the clinical arena. Nat Clin Pract Cardiovasc Med. 2004; 1(2): 96-102.

[2] Chu MJ, Vather R, Hickey AJ, et al. Impact of ischemic preconditioning on outcome in clinical liver surgery: a systematic review. Biomed Res Int. 2015; 2015: 370451.

[3] Lewis JH. The adaptive response (drug tolerance) helps to prevent drug-induced liver injury. Gastroenterol Hepatol (N Y). 2012; 8(5): 333-336.

[4] Lewis JE, Mello P, Knauer CM. Isoniazid-associated hepatitis-serum enzyme determinations and histologic features. West J Med. 1975; 122(5): 371-376.

[5] Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology. 2006; 43(3): 618-631.

[6] Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology. 1999; 29(2): 451-463.

[7] Bourdi M, Eiras DP, Holt MP, et al. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol. 2007; 20(2): 208-216.

[8] O’Brien PJ, Slaughter MR, Swain A, et al. Repeated acetaminophen dosing in rats: adaptation of hepatic antioxidant system. Hum Exp Toxicol. 2000; 19(5): 277-283.

[9] Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016; 36(2): 158-165.

[10] Thakore KN, Mehendale HM. Role of hepatocellular regeneration in CCl₄ autoprotection. Toxicol Pathol. 1991; 19(1): 47-58.

[11] Song G, Sharma AD, Roll GR, et al. MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology. 2010; 51(5): 1735-1743.

[12] Qu CF, Chen TY, Wang YT, et al. Primary prevention model of liver cancer in rural china. Zhonghua Zhong Liu Za Zhi. 2018; 40(7): 481-489.

[13] Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018; 10(4): 218.

[14] Kosaka N, Yoshioka Y, Hagiwara K, et al. Functional analysis of exosomal microRNA in cell-cell communication research. Methods Mol Biol. 2013; 1024: 1-10.

[15] Roderburg C, Luedde T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol. 2014; 61(6): 1434-1437.

[16] Su YW, Chen X, Jiang ZZ, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound-and herb-induced liver injury in rats. PLoS One. 2012; 7(5): e37395.

[17] Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 2009; 106(11): 4402-4407.

[18] Adams BD, Parsons C, Walker L, et al. Targeting noncoding RNAs in disease. J Clin Invest. 2017; 127(3): 761-771.

[19] Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal mir-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017; 35(2): 180-188.

[20] Conickx G, Avila CF, van den Berge M, et al. microRNA profiling in lung tissue and bronchoalveolar lavage of cigarette smoke-exposed mice and in COPD patients: a translational approach. Sci Rep. 2017; 7(1): 12871.

[21] Yang X, Weng Z, Mendrick DL, Shi Q. Circulating extracellular vesicles as a potential source of new biomarkers of drug-induced liver injury. Toxicol Lett. 2014; 225(3): 401-406.

[22] Lu X, Ji C, Tong W, et al. Integrated analysis of microRNA and mRNA expression profiles highlights the complex and dynamic behavior of toosendanin-induced liver injury in mice. Sci Rep. 2016; 6: 34225.

[23] Xia F, Zeng L, Yao XR, et al. Hepatic apoptosis and necrosis: mechanisms and clinical relevance. Liver Pathophysiol. 2017: 47-60.

[24] Nojima H, Freeman CM, Schuster RM, et al. Hepatocyte exosomes mediate liver repair and regeneration via sphingosine-1-phosphate. J Hepatol. 2016; 64(1): 60-68.

[25] Wang PW, Wu TH, Lin TY, et al. Characterization of the roles of vimentin in regulating the proliferation and migration of HSCs during hepatic fibrogenesis. Cells. 2019; 8(10): 1184.

[26] Battaglia RA, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration. F1000Res. 2018; 7: F1000.

[27] Patteson AE, Carroll RJ, Iwamoto DV, et al. The vimentin cytoskeleton: when polymer physics meets cell biology. Phys Biol. 2020; 18(1): 11001.

[28] Colucci-Guyon E, Portier MM, Dunia I, et al. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell. 1994; 79(4): 679-694.

[29] Haruna Y, Saito K, Spaulding S, et al. Identification of bipotential progenitor cells in human liver development. Hepatology. 1996; 23(3): 476-481.

[30] Taura K, Miura K, Iwaisako K, et al. Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology. 2010; 51(3): 1027-1036.

[31] Yang C, Dou R, Yin T, et al. miRNA-106b-5p in human cancers: diverse functions and promising biomarker. Biomed Pharmacother. 2020; 127: 110211.

[32] Xu X, Liu Z, Wang J, et al. miRNA profiles in livers with different mass deficits after partial hepatectomy and miR-106b˜25 cluster accelerating hepatocyte proliferation in rats. Sci Rep. 2016; 6: 31267.

[33] Ng R, Song G, Roll GR, et al. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest. 2012; 122(3): 1097-1108.

[34] Tsukita S, Yamada T, Takahashi K, et al. microRNAs 106b and 222 improve hyperglycemia in a mouse model of insulin-deficient diabetes via pancreatic β-cell proliferation. Ebiomedicine. 2017; 15: 163-172.

[35] Clemens MM, Mcgill MR, Apte U. Mechanisms and biomarkers of liver regeneration after drug-induced liver injury. Adv Pharmacol. 2019; 85: 241-262.

[36] Lai R, Xiang X, Mo R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol. 2015; 63(1): 148-155.

[37] Li M, Sun X, Zhao J, et al. CCL₅ deficiency promotes liver repair by improving inflammation resolution and liver regeneration through M2 macrophage polarization. Cell Mol Immunol. 2020; 17(7): 753-764.

[38] Cheng F, Eriksson JE. Intermediate filaments and the regulation of cell motility during regeneration and wound healing. Cold Spring Harb Perspect Biol. 2017; 9(9): a022046.

[39] Eckes B, Colucci-Guyon E, Smola H, et al. Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci. 2000; 113(13): 2455-2462.

[40] Bargagna-Mohan P, Paranthan RR, Hamza A, et al. Corneal antifibrotic switch identified in genetic and pharmacological deficiency of vimentin. J Biol Chem. 2012; 287(2): 989-1006.

[41] Rowe RG, Lin Y, Shimizu-Hirota R, et al. Hepatocyte-derived snail1 propagates liver fibrosis progression. Mol Cell Biol. 2011; 31(12): 2392-2403.

[42] Lu B, Xu Y, Xu L, et al. Mechanism investigation of dioscin against CCl₄-induced acute liver damage in micee. Environ Toxicol Pharmacol. 2012; 34(2): 127-135.

[43] Lovisa S, Lebleu VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015; 21(9): 998-1009.

[44] Ishida Y, Zhang S, Kuninaka Y, et al. Essential involvement of neutrophil elastase in acute acetaminophen hepatotoxicity using BALB/c mice. Int J Mol Sci. 2023; 24(9): 7845.

[45] Kim YH, Hwang JH, Kim KS, et al. Metformin ameliorates acetaminophen hepatotoxicity via Gadd45β-dependent regulation of JNK signaling in mice. J Hepatol. 2015; 63(1): 75-82.

[46] Zheng J, Yu L, Chen W, et al. Circulating exosomal microRNAs reveal the mechanism of fructus meliae toosendan-induced liver injury in mice. Sci Rep. 2018; 8(1): 2832.

[47] Mcginnis CS, Murrow LM, Gartner ZJ. Doubletfinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019; 8(4): 329-337.

[48] Yu G, Wang LG, Han Y, et al. Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5): 284-287.

[49] Borlak J, van Bommel F, Berg T. N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Liver Int. 2018; 38(2): 365-376.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.